Matthew Dickson
Cardiovascular Disease · Rockwall, TXNPI 1588806749
Payments from drug & device makers
Across 379 payments — averaging $18.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$837
- Merck$713
- Novartis$646
- Esperion Therapeutics, Inc.$540
- Johnson & Johnson$497
- E.r. Squibb & Sons, L.L.C.$496
- plus $3K from 27 others
What the payments were for
- Food & beverage$7,06299%
- Other$561%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 45 | $837 |
| Merck | 36 | $713 |
| Novartis | 34 | $646 |
| Esperion Therapeutics, Inc. | 33 | $540 |
| Johnson & Johnson | 36 | $497 |
| E.r. Squibb & Sons, L.L.C. | 29 | $496 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 17 | $427 |
| Actelion Pharmaceuticals US, Inc. | 18 | $404 |
| Boehringer Ingelheim | 18 | $310 |
| Amgen | 20 | $303 |
| Boston Scientific | 10 | $259 |
| Heartflow, Inc. | 3 | $215 |
| AstraZeneca | 12 | $200 |
| Kiniksa Pharmaceuticals, Ltd. | 8 | $181 |
| Regeneron Healthcare Solutions, Inc. | 8 | $117 |
| Baxter Healthcare | 3 | $110 |
| Kowa Pharmaceuticals America, Inc. | 6 | $104 |
| Lexicon Pharmaceuticals, Inc. | 4 | $97 |
| Bayer | 5 | $92 |
| Amarin Pharma, Inc. | 5 | $82 |
| Scpharmaceuticals Inc. | 4 | $67 |
| Astellas Pharma US Inc | 3 | $50 |
| Sanofi-aventis U.S. LLC | 3 | $50 |
| Philips North America LLC | 3 | $49 |
| Inspire Medical Systems, Inc. | 2 | $47 |
| Bardy Diagnostics, Inc. | 1 | $41 |
| Cvrx, Inc. | 2 | $38 |
| Medtronic | 2 | $32 |
| Lilly USA, LLC | 2 | $31 |
| Arbor Pharmaceuticals, Inc. | 2 | $26 |
| Vivaquant Inc, Dba Rhythm Express | 3 | $23 |
| Novo Nordisk | 1 | $18 |
| United Therapeutics Corporation | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FFRct$133
How this compares
$7,117 in reported general payments places this provider in the 60th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 840 | $1,006,807 |
| XareltoRivaroxaban | 125 | $147,763 |
| EntrestoSacubitril/Valsartan | 80 | $118,103 |
| Repatha SureclickEvolocumab | 53 | $75,851 |
| JardianceEmpagliflozin | 46 | $71,329 |
| Repatha PushtronexEvolocumab | 78 | $69,501 |
| NexlizetBempedoic Acid/Ezetimibe | 80 | $59,065 |
| Repatha SyringeEvolocumab | 20 | $31,443 |
| Metoprolol Succinate | 1,571 | $22,990 |
| Atorvastatin Calcium | 2,099 | $21,479 |
| Praluent PenAlirocumab | 13 | $17,512 |
| Ezetimibe | 754 | $15,228 |
| FarxigaDapagliflozin Propanediol | 17 | $14,439 |
| Rosuvastatin Calcium | 830 | $9,903 |
| Lisinopril | 909 | $6,727 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $837 | $1,006,807840 claims |
| Johnson & JohnsonXarelto | $497 | $147,763125 claims |
| NovartisEntresto | $646 | $118,10380 claims |
| Boehringer IngelheimJardiance | $310 | $71,32946 claims |
| Esperion Therapeutics, Inc.Nexlizet | $540 | $59,06580 claims |
| AstraZenecaFarxiga | $200 | $14,43917 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $104 | $4,30713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Rockwall
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
- James FeldmanHouston$3.1M
- Fernando BoccalandroOdessa$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.